Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀº 2025³â 177¾ï ´Þ·¯¸¦ Â÷ÁöÇϸç, ¿¹Ãø ±â°£ µ¿¾È CAGRÀº 12.7%¸¦ ³ªÅ¸³» 2032³â¿¡´Â 408¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.
½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ(RTHMS)Àº °³ÀÎÀÇ »ý¸®Àû µ¥ÀÌÅ͸¦ Áö¼ÓÀûÀ¸·Î ¼öÁý, ºÐ¼®, ÇØ¼®ÇÏ°í °Ç° »óŸ¦ ½Ç½Ã°£À¸·Î Æò°¡ÇÏ´Â ±â¼ú Á᫐ ÇÁ·¹ÀÓ¿öÅ©ÀÔ´Ï´Ù. ¼¾¼, ¿þ¾î·¯ºí µð¹ÙÀ̽º, IoT ±â¼úÀ» »ç¿ëÇÏ¿© ½É¹Ú¼ö, Ç÷¾Ð, »ê¼Ò Æ÷ȵµ, ü¿Â µîÀÇ »ýü ½ÅÈ£¸¦ ÃøÁ¤ÇÕ´Ï´Ù. ½Ã½ºÅÛÀº ÀÌ µ¥ÀÌÅ͸¦ Áï½Ã ó¸®Çϰí, Á¾Á¾ ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© ÀÌ»óÀ» °¨ÁöÇϰí ÀáÀçÀûÀÎ °Ç° ¹®Á¦¸¦ ¿¹ÃøÇÕ´Ï´Ù. ½É°¢ÇÑ º¯È°¡ °¨ÁöµÇ¸é ȯÀÚ, °¡Á·, ÀÇ·á Á¦»ê¾÷ü¿¡°Ô Áï°¢ÀûÀÎ °æ°í¸¦ Á¦°øÇÏ¿© Àû½Ã¿¡ °³ÀÔÇÏ°í ±¸¸íÇÒ ¼ö ÀÖ´Â Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
¸¸¼º ÁúȯÀÇ À¯º´·ü »ó½Â
´ç´¢º´, ½ÉÇ÷°üÁúȯ, È£Èí±âÁúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀ» °·ÂÈ÷ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº ȯÀÚÀÇ °Ç°À» È¿°úÀûÀ¸·Î °ü¸®Çϰí ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ Áö¼ÓÀûÀ̰í Á¤È®ÇÑ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº ºñÁ¤»óÀûÀÎ ½Ã±â ÀûÀýÇÑ °¨Áö, ¸ÂÃã Ä¡·á Á¶Á¤, ȯÀÚ °á°ú °³¼±À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á Çʿ伺 Áõ°¡´Â ÀÇ·á½Ã¼³ ¹× ÀçÅà °ü¸®ÀÇ ÇöÀå¿¡¼ÀÇ º¸±ÞÀ» µÞ¹ÞħÇϰí, ÀÌ·¯ÇÑ ±â¼úÀ» Çö´ëÀûÀÌ°í ¿¹¹æÀûÀΠȯÀÚ Áß½ÉÀÇ °Ç° °ü¸®¿¡ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸® ¸Å±èÇϰí ÀÖ½À´Ï´Ù.
³ôÀº Ãʱ⠺ñ¿ë
½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ Ãʱ⠺ñ¿ëÀÌ ³ôÀº °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÷´Ü ÀåÄ¡, ¼¾¼ ¹× ÅëÇÕ ±â¼úÀº »ó´çÇÑ ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ¼Ò±Ô¸ð ÀÇ·á½Ã¼³ ¹× ºñ¿ë¿¡ ¹Î°¨ÇÑ Áö¿ª ȯÀÚ¿¡°Ô´Â »ç¿ëÇϱⰡ ¾î·Æ½À´Ï´Ù. ÀÌ °æÁ¦Àû ºÎ´ãÀº ƯÈ÷ °æÁ¦Àû ¿©À¯°¡ Áß¿äÇÑ °ü½É»çÀÎ ½ÅÈï°æÁ¦±¹¿¡¼ÀÇ º¸±ÞÀ» ÀúÇØÇϰí, ½ÃÀåÀÇ È®´ë³ª ±â¼ú ÁÖµµÀÇ ½Ã±â ÀûÀýÇÑ ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ Á¦°øÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.
±â¼ú Áøº¸
±â¼ú Áøº¸´Â ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î, IoT, AI, ¹ÙÀÌ¿À ¼¾¼, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ±â¼ú Çõ½ÅÀ¸·Î Á¤È®¼º°ú ¿¬°á¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¿øÈ°ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁý, ¿¹Ãø ºÐ¼®, °³ÀÎÈµÈ °Ç° ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© ȯÀÚÀÇ Âü¿©¿Í °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ ½º¸¶Æ® ¿þ¾î·¯ºí ¹× °í±Þ ¸ð´ÏÅ͸µ µµ±¸´Â °Ç° °ü¸® Á¦»ê¾÷ü°¡ Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ±â¼úÀÌ Áö¼ÓÀûÀ¸·Î ÁøÈÇÔ¿¡ µû¶ó ¸¸¼º Áúȯ °ü¸® ¹× ¿¹¹æ ÀÇÇп¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ¼¼°è º¸±ÞÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á
µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ ´ëÇÑ ¿ì·Á´Â ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ¹æÇØÇϰí ÀÖ½À´Ï´Ù. »çÀ̹ö °ø°Ý, µ¥ÀÌÅÍ À¯Ãâ, ±â¹Ð¼ºÀÌ ³ôÀº ȯÀÚ Á¤º¸¿¡ ´ëÇÑ ¹«´Ü ¾×¼¼½º À§ÇèÀº »ç¿ëÀÚ¿Í °Ç° °ü¸® Á¦»ê¾÷üµé »çÀÌ¿¡ ºÒ½ÅÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ ¿öÅ©¿Í ±ÔÁ¤ Áؼö ¿ä±¸ »çÇ×Àº µµÀÔÀ» º¹ÀâÇÏ°Ô ¸¸µé°í °³¹ßÀÚ¿Í ÀÇ·á Á¦»ê¾÷üÀÇ ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦´Â º¸±ÞÀ» ´ÊÃß°í ½ÃÀå¿¡¼ ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ ÀáÀç·ÂÀ» Á¦ÇÑÇÕ´Ï´Ù.
COVID-19ÀÇ ¿µÇâ
COVID-19ÀÇ ´ëÀ¯ÇàÀº ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ Ã¤¿ëÀ» Å©°Ô °¡¼ÓÈÇß½À´Ï´Ù. º´¿øÀÌ ¾ÐµµµÇ°í »çȸÀû °Å¸®°¡ ÇʼöÀûÀÌ µÇ´Â °¡¿îµ¥, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀº ¶óÀÌÇÁ ¶óÀÎÀÌ µÇ¾î, ÁýÀ¸·ÎºÎÅÍÀÇ Áö¼ÓÀûÀÎ Äɾ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. FDA°¡ ½ÂÀÎÇÑ RPM Àåºñ µîÀÇ ±ÔÁ¦ Áö¿øÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇß½À´Ï´Ù. ÀÌ À§±â´Â ¿þ¾î·¯ºí ±â¼ú°ú ¿ø°Ý ÀÇ·áÀÇ °¡Ä¡¸¦ ºÎ°¢½Ã۰í Çõ½Å°ú ½Ç½Ã°£ ¸ð´ÏÅ͸µÀÇ ÁÖ·ù °Ç° °ü¸®¿¡ Àå±âÀûÀÎ ÅëÇÕÀ» ÃËÁøÇß½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¼ÒÇÁÆ®¿þ¾î ºÐ¾ß°¡ ÃÖ´ë鵃 Àü¸Á
¼ÒÇÁÆ®¿þ¾î ºÎ¹®Àº °í±Þ ºÐ¼®, °³ÀÎÈµÈ °Ç° ÀλçÀÌÆ®À¸·Î ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. AI Á᫐ Ç÷§Æû, ¸ð¹ÙÀÏ ¾Û, Ŭ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚ¿Í °Ç° °ü¸® Á¦»ê¾÷ü´Â Áß¿äÇÑ °Ç° Á¤º¸¿¡ ½Ç½Ã°£À¸·Î ¾×¼¼½ºÇÒ ¼ö ÀÖ¾î ½Ã±â ÀûÀýÇÑ °³ÀÔÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº Á÷°üÀûÀÎ ÀÎÅÍÆäÀ̽º¿Í ¿ø°Ý ¿¬°áÀ» ÅëÇØ »ç¿ëÀÚ °æÇèÀ» Çâ»ó½ÃŰ°í °Ç° °ü¸®¸¦º¸´Ù Àû±ØÀûÀ̰í ȯÀÚ Áß½ÉÀ¸·Î ¸¸µé¾î ½ÃÀå ¼ºÀå°ú º¸±ÞÀ» Å©°Ô Çâ»ó½Ãŵ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ´ç´¢º´ °ü¸® ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ Àü¸Á
¿¹Ãø ±â°£ µ¿¾È ¼¼°è ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´ °ü¸® ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áö¼ÓÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ ±â±â, ¿þ¾î·¯ºí ¼¾¼, ¸ð¹ÙÀÏ Çコ ¿ëµµ´Â ȯÀÚ¿¡°Ô ½Ç½Ã°£À¸·Î Æ÷µµ´ç ¼öÁØÀ» ÃßÀûÇÏ´Â ´É·ÂÀ» Á¦°øÇÏ¿© ´õ ³ªÀº Áúº´ °ü¸® ¹× ÇÕº´Áõ °¨¼Ò¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. AI ÁÖµµ ºÐ¼®°ú ¿ø°Ý ÀÇ·á ÅëÇÕÀº °³ÀÎÈ °ü¸®¸¦ ´õ¿í °ÈÇÏ°í °íµµ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ´Éµ¿ÀûÀÎ ´ç´¢º´ °ü¸®¿¡ ´ëÇÑ °ÇÑ ¿ä±¸´Â ¼¼°èÀÇ Çõ½Å, ä¿ë ¹× ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇÕ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °Ç° °ü¸®ÀÇ µðÁöÅÐÈÀÇ ÁøÀü, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ ½º¸¶Æ®Æù »ç¿ë·ü Áõ°¡, ÀÎÅÍ³Ý Á¢¼Ó Çâ»ó, ¿ø°Ý ÀÇ·á¿¡ ´ëÇÑ Á¤ºÎ ÇÁ·Î±×·¥ÀÇ Àå·Á µîÀÌ º¸±Þ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ±Þ¼ÓÇÑ ³ëÈ¿Í À¯Çà ÈÄ °Ç° ÀÇ½Ä Áõ°¡´Â ÃÖ÷´Ü ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÅõÀÚ¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼Ò°¡ °áÇյʿ¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ±â¼úÀÇ ÁÖ¿ä Áß½ÉÁö·Î ÀÚ¸®¸Å±èÇÏ´Â À¯¸®ÇÑ ±â¼¼¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµÇ´Âµ¥, ÀÌ´Â °í±Þ ÀÇ·á ÀÎÇÁ¶ó¿Í µðÁöÅÐ °Ç° ±â¼úÀÇ ³ôÀº ä¿ë·ü ¶§¹®ÀÔ´Ï´Ù. ¸¸¼º Áúȯ Áõ°¡¿Í ³ëÈ·Î ÀÎÇØ Áö¼ÓÀûÀÎ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. AI, ¿þ¾î·¯ºí µð¹ÙÀ̽º, Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀÇ ÅëÇÕÀº Áø´Ü Á¤È®µµ¿Í ȯÀÚ Âü¿©µµ¸¦ ³ôÀÔ´Ï´Ù. Áö¿ø »óȯ Á¤Ã¥°ú °·ÂÇÑ R&D ÅõÀÚ´Â Çõ½ÅÀ» ´õ¿í °¡¼ÓÈÇÏ°í ºÏ¹Ì¸¦ ½Ç½Ã°£ Çコ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ ¼¼°è ¸®´õ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Real-Time Health Monitoring System Market is accounted for $17.7 billion in 2025 and is expected to reach $40.8 billion by 2032 growing at a CAGR of 12.7% during the forecast period. A Real-Time Health Monitoring System (RTHMS) is a technology-driven framework that continuously collects, analyzes, and interprets physiological data from an individual to assess their health status in real-time. Using sensors, wearable devices, and IoT technology, it measures vital signs such as heart rate, blood pressure, oxygen saturation, and body temperature. The system processes this data instantly, often using machine learning algorithms, to detect anomalies or predict potential health issues. If a critical change is detected, it can trigger an immediate alert to the patient, their family, or healthcare providers, enabling timely intervention and potentially life-saving care.
Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and respiratory ailments is strongly driving the Real-Time Health Monitoring System Market. These conditions demand continuous and accurate monitoring to manage patient health effectively and prevent complications. Real-time monitoring systems enable timely detection of anomalies, personalized treatment adjustments, and improved patient outcomes. This growing medical necessity fuels widespread adoption across healthcare facilities and homecare settings, positioning these technologies as indispensable tools in modern, preventive, and patient-centered healthcare.
High Initial Cost
The high initial cost of real-time health monitoring systems poses a significant barrier to market growth. Advanced devices, sensors, and integration technologies demand substantial investment, making them less accessible to small healthcare facilities and patients in cost-sensitive regions. This financial burden discourages widespread adoption, particularly in developing economies, where affordability is a key concern, thereby hindering the market's potential to expand and deliver timely, technology-driven healthcare solutions.
Technological Advancements
Technological advancements are a key driver of the Real-Time Health Monitoring System Market, with innovations in IoT, AI, biosensors, and cloud computing enhancing accuracy and connectivity. These breakthroughs enable seamless real-time data collection, predictive analytics, and personalized health insights, improving patient engagement and outcomes. Smart wearables and advanced monitoring tools also support healthcare providers in delivering timely interventions. As technology continues to evolve, it is revolutionizing chronic disease management and preventive care, accelerating the global adoption of real-time monitoring systems.
Data Privacy and Security Concerns
Data privacy and security concerns are significantly hindering the growth of the Real-Time Health Monitoring System Market. The risk of cyberattacks, data breaches, and unauthorized access to sensitive patient information creates distrust among users and healthcare providers. Strict regulatory frameworks and compliance requirements further complicate adoption, increasing costs for developers and providers. These challenges slow down widespread implementation, limiting the full potential of real-time health monitoring solutions in the market.
Covid-19 Impact
The COVID-19 pandemic significantly accelerated the adoption of real-time health monitoring systems. With hospitals overwhelmed and social distancing essential, remote patient monitoring became a lifeline, enabling continuous care from home. Regulatory support, such as FDA-approved RPM devices, boosted market growth. The crisis highlighted the value of wearable tech and telehealth, driving innovation and long-term integration of real-time monitoring into mainstream healthcare.
The software segment is expected to be the largest during the forecast period
The software segment is expected to account for the largest market share during the forecast period, due to advanced analytics, and personalized health insights. With increasing reliance on AI-driven platforms, mobile apps, and cloud-based solutions, patients and healthcare providers gain real-time access to critical health information, ensuring timely interventions. These software solutions also enhance user experience through intuitive interfaces and remote connectivity, making healthcare more proactive and patient-centric, thereby significantly boosting market growth and adoption.
The diabetes management segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the diabetes management segment is predicted to witness the highest growth rate, due to rising prevalence of diabetes worldwide. Continuous glucose monitoring devices, wearable sensors, and mobile health applications empower patients to track glucose levels in real-time, enabling better disease management and reducing complications. Integration of AI-driven analytics and telemedicine further enhances personalized care, fostering demand for advanced monitoring solutions. This strong need for proactive diabetes care is boosting innovation, adoption, and market expansion globally.
During the forecast period, the Asia Pacific region is expected to hold the largest market share because of the growing demand for remote patient monitoring, the increasing digitization of healthcare, and the rising prevalence of chronic diseases. Adoption is further fueled by rising smartphone usage, better internet access, and encouraging government programs for telehealth. Furthermore, investments in cutting-edge monitoring systems are encouraged by a fast aging population and increased health consciousness following the pandemic. When combined, these elements generate a favorable momentum that positions Asia-Pacific as a major center for real-time health monitoring technologies.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure and high adoption of digital health technologies. With increasing prevalence of chronic diseases and aging populations, demand for continuous, remote patient monitoring is surging. Integration of AI, wearable devices, and cloud-based platforms enhances diagnostic accuracy and patient engagement. Supportive reimbursement policies and strong R&D investments further accelerate innovation, positioning North America as a global leader in real-time health monitoring solutions.
Key players in the market
Some of the key players profiled in the Real-Time Health Monitoring System Market include Medtronic, Philips Healthcare, GE HealthCare, Siemens Healthineers, Abbott Laboratories, Boston Scientific, Dexcom, Omron Healthcare, Garmin, Apple Inc., Samsung Electronics, iRhythm Technologies, Withings, Masimo Corporation, ResMed, AliveCor, Huawei Technologies and Xiaomi Corporation.
In July 2025, Medtronic and Philips have signed a multiyear strategic partnership to expand global access to patient monitoring solutions, integrating Medtronic technologies like Nellcor(TM) pulse oximetry, Microstream(TM) capnography, and BIS(TM) brain monitoring into Philips systems. They'll bundle ECG, NIBP, and battery consumables and launch a pledge program for clinical validation, cybersecurity, and readiness, simplifying procurement and enhancing care.
In May 2025, Medtronic has entered a new exclusive distribution agreement with Corsano Health to bring its multi parameter, medical grade wearable devices to Western Europe. Targeted for hospital and hospital at home settings, the wearable supports remote monitoring and signals an expansion of Medtronic's Acute Care & Monitoring portfolio in the region.
In April 2025, Medtronic announced that it has entered a U.S. distribution agreement with Dragonfly(TM) Endoscopy, Inc. This strategic collaboration brings the Dragonfly(TM) pancreaticobiliary imaging system into Medtronic's distribution network. The partnership aims to enhance innovation in diagnosing and treating pancreatic and bile duct disorders, expanding physician access to advanced endoscopic solutions in the U.S.